News
Zacks.com on MSN7h
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
GlobalData on MSN16h
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received conditional marketing approval from the European Commission for its liver ...
Everyday Health on MSN21h
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $485 from $483 and keeps an Outperform rating on the shares ...
CONSHOHOCKEN, PA, USA I August 19, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback